<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Special AT-rich sequence-binding protein 2 (SATB2) is a novel diagnostic marker of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), and loss of SATB2 has been linked to poor survival from the disease </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we validated the prognostic ability of SATB2 expression in a large, prospective <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cohort </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Immunohistochemical SATB2 expression was assessed in 527 incident <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cases from the Malm√∂ Diet and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Study </plain></SENT>
<SENT sid="3" pm="."><plain>Kaplan-Meier analysis and Cox proportional hazards modelling were used to explore the impact of SATB2 expression on <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survival (CSS) and overall survival (OS) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: High SATB2 expression was associated with a prolonged CSS in the full cohort (hazard ratio (HR)=0.61; 95% CI 0.41-0.92) and in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> (HR=0.39; 95% CI 0.20-0.75), remaining significant in multivariable analysis of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> (HR=0.49; 95% CI 0.25-0.96), with similar findings for OS </plain></SENT>
<SENT sid="5" pm="."><plain>In curatively resected stage III-IV patients, a significant benefit from adjuvant and/or neoadjuvant therapy was observed for SATB2 high <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> (P(interaction)=0.037 for OS) and high SATB2 expression in <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> correlated with an enhanced effect of neoadjuvant therapy (P(interaction)=0.033 for OS) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: High SATB2 expression is an independent marker of good prognosis in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> and may modulate sensitivity to chemotherapy and radiation </plain></SENT>
</text></document>